<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00575328</url>
  </required_header>
  <id_info>
    <org_study_id>2007-P-001471</org_study_id>
    <nct_id>NCT00575328</nct_id>
  </id_info>
  <brief_title>Study of Maca Root to Treat Sexual Dysfunction Associated With the Treatment Regimen for Bipolar Disorder in Females</brief_title>
  <official_title>A Double-Blind, Placebo Controlled Study of Maca Root for the Treatment of Sexual Dysfunction Associated With the Treatment Regimen for Bipolar Disorder in Females</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Alliance for Research on Schizophrenia and Depression</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to find out whether Maca Root is effective for treating&#xD;
      sexual dysfunction in females that is caused by the treatment for bipolar disorder. An&#xD;
      additional aim of the study is to document the safety and tolerability of maca root, as well&#xD;
      as any potential side effects that it causes. We suspect that Maca Root will result in a&#xD;
      significant reduction in sexual dysfunction when compared to a placebo group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study seeks to enroll 80 patients with sexual dysfunction associated with their bipolar&#xD;
      medication regimen over 24 months. Subjects were outpatient females between 18 and 80 years&#xD;
      old with no significant symptoms of mania (Young Mania Rating Scale score&lt;10), and who have&#xD;
      been on a steady regimen of medications to treat bipolar disorder for at least 8 weeks, with&#xD;
      a stable dose for at least 4 weeks. Subjects will be randomly assigned in a double blind&#xD;
      manner to receive 3000 mg/day of maca root or identical placebo for 12 weeks to determine&#xD;
      whether maca root is more effective than placebo for the treatment of sexual dysfunction&#xD;
      associated with treatment regimens for bipolar disorder.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Only N=8 subjects randomized; funding ran out; too small N to yield useful data.&#xD;
  </why_stopped>
  <start_date type="Actual">February 26, 2008</start_date>
  <completion_date type="Actual">April 26, 2010</completion_date>
  <primary_completion_date type="Actual">April 26, 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Maca root will be compared against inactive placebo as a treatment for sexual dysfunction induced by psychotropic drugs.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>All subjects, investigators, and clinical assessors were blinded to the intervention.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Reductions in Arizona Sexual Experience Scale (ASEX) Scores Over 12 Weeks of Treatment.</measure>
    <time_frame>Biweekly from Baseline (week zero) to 12 weeks</time_frame>
    <description>The ASEX scale consists of five items rating sexual drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. The range of total score is from 5-30, with the higher scores indicating greater sexual dysfunction. Scores were obtained at baseline and at all biweekly assessment visits over the 12 weeks of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reductions in Massachusetts General Hospital Sexual Dysfunction (MGH-SD) Inventory Scores Over 12 Weeks of Treatment.</measure>
    <time_frame>Biweekly from Baseline (week zero) to 12 weeks</time_frame>
    <description>This instrument is composed of five items evaluating libido, sexual arousal or excitement, ability to achieve orgasm, ability to achieve and maintain an erection (for men only) and overall sexual satisfaction. Items are rated on a scale of 1 to 6 with a rating of 1 indicating greater than normal functioning and a rating of 6 indicating totally absent functioning. Possible total scores range from 5-30, with higher scores indicating greater pathology. Scores were obtained at baseline and at each biweekly assessment visit over 12 weeks of treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Sexual Dysfunction</condition>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Maca Root</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will be given 3g/day of Maca Root.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in this arm will receive inactive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maca Root</intervention_name>
    <description>3g/day of Maca Root for 12 weeks.</description>
    <arm_group_label>Maca Root</arm_group_label>
    <other_name>Lepidium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo provided by research pharmacy daily for 12 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Inactive placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is female, age 18 to 80 years&#xD;
&#xD;
          -  Subject has been on a steady regimen to treat bipolar disorder, including monotherapy&#xD;
             with or any combination of antidepressants, mood stabilizers, atypical antipsychotics,&#xD;
             or benzodiazepines, for at least 8 weeks; and is currently on a stable dose of that&#xD;
             regimen for at least 4 weeks&#xD;
&#xD;
          -  Subject is currently euthymic (Hamilton-D scale score &lt; 10) and is without significant&#xD;
             anxiety symptoms (Hamilton-A &lt; 10). Her bipolar disorder must be in remission (Young&#xD;
             Mania Rating Scale score &lt; 10)&#xD;
&#xD;
          -  Subject must have had no sexual dysfunction prior to taking psychotropic medications&#xD;
             and there must be a clear temporal relationship between the sexual dysfunction and the&#xD;
             treatment for bipolar disorder&#xD;
&#xD;
          -  Subject must have been consistently experiencing at least one of the following&#xD;
             criteria for at least 4 weeks, with distress or disability:&#xD;
&#xD;
          -  Inability to have an orgasm, according to patient opinion&#xD;
&#xD;
          -  Clinically significant orgasm delay with masturbation or intercourse&#xD;
&#xD;
          -  Inability to attain or maintain until completion of sexual activity an adequate&#xD;
             lubrication swelling response of sexual excitement&#xD;
&#xD;
          -  Decreased libido according to patient opinion&#xD;
&#xD;
          -  Subject must be having or had been having some form of regular sexual activity&#xD;
             (masturbation, oral sex, intercourse) at least twice monthly prior to the bipolar&#xD;
             treatment regimen and is willing to continue efforts at sexual activity at least once&#xD;
             weekly for the duration of the study&#xD;
&#xD;
          -  Subject must be in good general physical health&#xD;
&#xD;
          -  Subject must be able to understand and communicate in English&#xD;
&#xD;
          -  Subject must have given informed consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Primary or prior diagnosis of a sexual disorder (other than the side effect of the&#xD;
             bipolar medication or symptom of the bipolar disorder)&#xD;
&#xD;
          -  Sexual dysfunction secondary to general underlying medical condition&#xD;
&#xD;
          -  Penile, vaginal, clitoral or other sexual organ anatomical deformities&#xD;
&#xD;
          -  Any uncontrolled psychiatric disorder&#xD;
&#xD;
          -  Alcohol or substance abuse or dependence within the past six months&#xD;
&#xD;
          -  Recent major relationship changes, disruption, or turmoil ongoing or anticipated which&#xD;
             are unrelated to her sexual dysfunction&#xD;
&#xD;
          -  Blood pressure outside the range of 90/50 - 170/100&#xD;
&#xD;
          -  Known hyperprolactinemia&#xD;
&#xD;
          -  Use of investigational drugs within previous 3 months or during study&#xD;
&#xD;
          -  Current use of other drugs for sexual dysfunction or other therapies or medications to&#xD;
             treat sexual dysfunction&#xD;
&#xD;
          -  Current use of nefazodone&#xD;
&#xD;
          -  Hormone replacement therapy, unless patient has been on stable dose of hormone therapy&#xD;
             for at least 3 mo prior to the bipolar treatment regimen and had no sexual dysfunction&#xD;
             while on the same hormone therapy regimen, and there is no change in the hormone&#xD;
             replacement therapy during the study&#xD;
&#xD;
          -  Pregnancy, lactating, or planning to become pregnant during the study&#xD;
&#xD;
          -  Child bearing potential subjects unwilling and/or not prepared and/or who are judged&#xD;
             unreliable to use an acceptable and verifiable form of contraception during the study&#xD;
&#xD;
          -  Any clinically significant abnormality on the screening physical examination&#xD;
&#xD;
          -  History of hormonal cancers&#xD;
&#xD;
          -  Any medical or psychological condition or social circumstances that would impair&#xD;
             subject's ability to participate reliably in the study, or that may increase the risk&#xD;
             to subjects or others as a result of participating in this study&#xD;
&#xD;
          -  Dyspareunia secondary to an inflammatory or anatomical condition&#xD;
&#xD;
          -  Prior use of maca for at least two weeks&#xD;
&#xD;
          -  Infection of the urogenital tract that may make sexual activity painful or difficult&#xD;
&#xD;
          -  Subjects whose sexual partners are suffering from and/or receiving treatment for&#xD;
             sexual dysfunction&#xD;
&#xD;
          -  Receiving psychosexual or other therapy for sexual dysfunction and not willing to&#xD;
             discontinue that treatment at screening&#xD;
&#xD;
          -  Subjects who do not understand and communicate in English&#xD;
&#xD;
          -  Subjects for whom sexual activity is inadvisable&#xD;
&#xD;
          -  Subjects whose sexual dysfunction is considered to be situational&#xD;
&#xD;
          -  Subjects not attempting some form of regular sexual activity at least twice monthly&#xD;
             and at least once weekly during study visit intervals for duration of entire study&#xD;
&#xD;
          -  Changes in bipolar medication and/or dose of medication within the last 4 weeks before&#xD;
             baseline visit&#xD;
&#xD;
          -  Participants on medications with a narrow therapeutic window or low therapeutic index&#xD;
             for which small variations may be harmful given the lack of systematic experience with&#xD;
             drug-supplement interactions (i.e. - cyclosporine, digoxin, warfarin, and&#xD;
             antiretrovirals)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christina Dording, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Mischoulon, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Depression Clinical and Research Program, Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>December 14, 2007</study_first_submitted>
  <study_first_submitted_qc>December 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2007</study_first_posted>
  <results_first_submitted>August 6, 2020</results_first_submitted>
  <results_first_submitted_qc>August 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 7, 2020</results_first_posted>
  <last_update_submitted>September 5, 2020</last_update_submitted>
  <last_update_submitted_qc>September 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>David Mischoulon, MD, PhD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Sexual Dysfunction</keyword>
  <keyword>Bipolar Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan for data sharing at this time. Study was never completed and did not have enough subjects to yield useful data.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Female subjects with remitted bipolar disorder and sexual dysfunction associated with their bipolar medication treatment regimens were recruited from 2/26/2008 to 4/26/2010, all at the Massachusetts General Hospital Depression Clinical and Research Program.</recruitment_details>
      <pre_assignment_details>Subjects underwent a screening visit to determine eligibility. Those subjects deemed eligible returned a week later for a baseline visit, where eligibility was confirmed prior to treatment assignment. Subjects who for any reason no longer met entry criteria were discontinued and offered alternative treatment options.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Maca Root</title>
          <description>Subjects in this arm will be given 3g/day of Maca Root.&#xD;
Maca Root: 3g/day of Maca Root for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Subjects in this arm will receive inactive placebo.&#xD;
Placebo: Placebo provided by research pharmacy daily for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Maca Root</title>
          <description>Subjects in this arm will be given 3g/day of Maca Root.&#xD;
Maca Root: 3g/day of Maca Root for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Subjects in this arm will receive inactive placebo.&#xD;
Placebo: Placebo provided by research pharmacy daily for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37" spread="11"/>
                    <measurement group_id="B2" value="37" spread="10"/>
                    <measurement group_id="B3" value="37" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Location: Massachusetts General Hospital, Depression Clinical and Research Program, Boston, Massachusetts, USA</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hamilton D-17 score</title>
          <description>The 17-item Hamilton Rating Scale for Depression (HAM-D-17) is a structured interview completed by the clinician based on assessment of patient's depressive symptoms. It quantifies degree and severity of depression. Higher scores indicate greater pathology. Possible range of scores is from zero (no symptoms) to 52 (very severe symptoms). Scores of 10 or less are considered to have no significant depression (11-15=mild, 16-22=moderate, &gt;23= severe). For entry, subjects were required to have a score of less than 10.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6" spread="3"/>
                    <measurement group_id="B2" value="6" spread="2"/>
                    <measurement group_id="B3" value="6" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Young Mania Rating Scale score</title>
          <description>Young Mania Rating Scale (YMRS) has 11 items to assess severity of mania in patients with bipolar disorder. The items in this scale reflect core symptoms of the manic phase of bipolar disorder. YMRS total score ranges from 0 to 60; higher scores indicate more severe mania, thus, a negative change (or decrease) from baseline indicates a reduction in manic symptoms. Total score â‰¤12 indicates remission (13-19=minimal symptoms; 20-25=mild mania, 26-37=moderate mania, 38-60=severe mania). Scores &lt;10 are considered fully euthymic. For entry, subjects were required to have a score of less than 10.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2" spread="1.8"/>
                    <measurement group_id="B2" value="1.5" spread="1.7"/>
                    <measurement group_id="B3" value="1.8" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reductions in Arizona Sexual Experience Scale (ASEX) Scores Over 12 Weeks of Treatment.</title>
        <description>The ASEX scale consists of five items rating sexual drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. The range of total score is from 5-30, with the higher scores indicating greater sexual dysfunction. Scores were obtained at baseline and at all biweekly assessment visits over the 12 weeks of treatment.</description>
        <time_frame>Biweekly from Baseline (week zero) to 12 weeks</time_frame>
        <population>Intent to treat sample. Subjects with at least one post baseline visit recorded with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Maca Root</title>
            <description>Subjects in this arm will be given 3g/day of Maca Root.&#xD;
Maca Root: 3g/day of Maca Root for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects in this arm will receive inactive placebo.&#xD;
Placebo: Placebo provided by research pharmacy daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Reductions in Arizona Sexual Experience Scale (ASEX) Scores Over 12 Weeks of Treatment.</title>
          <description>The ASEX scale consists of five items rating sexual drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. The range of total score is from 5-30, with the higher scores indicating greater sexual dysfunction. Scores were obtained at baseline and at all biweekly assessment visits over the 12 weeks of treatment.</description>
          <population>Intent to treat sample. Subjects with at least one post baseline visit recorded with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ASEX-Baseline Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.7" spread="1.5"/>
                    <measurement group_id="O2" value="21.3" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASEX-Final Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3" spread="3.8"/>
                    <measurement group_id="O2" value="23" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASEX-Change in Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="4.2"/>
                    <measurement group_id="O2" value="1.5" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There will be no difference in clinical improvement (i.e. change in ASEX score) between treatment arms. No formal power analysis was carried out, given the small study sample.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Analysis is a test of statistical significance to evaluate whether the results are consistent with the assumption of there being no difference in the clinical improvement (i.e. change in ASEX score) of the two treatments (null hypothesis).</non_inferiority_desc>
            <p_value>0.62</p_value>
            <p_value_desc>No adjustment for multiple comparisons. P value for significance set a priori at P&lt;0.05.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.8</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>3.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.7</ci_lower_limit>
            <ci_upper_limit>12.3</ci_upper_limit>
            <other_analysis_desc>The analysis is not truly informative, since the analyzable sample (n=6) was too small. Results should be viewed with caution.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Reductions in Massachusetts General Hospital Sexual Dysfunction (MGH-SD) Inventory Scores Over 12 Weeks of Treatment.</title>
        <description>This instrument is composed of five items evaluating libido, sexual arousal or excitement, ability to achieve orgasm, ability to achieve and maintain an erection (for men only) and overall sexual satisfaction. Items are rated on a scale of 1 to 6 with a rating of 1 indicating greater than normal functioning and a rating of 6 indicating totally absent functioning. Possible total scores range from 5-30, with higher scores indicating greater pathology. Scores were obtained at baseline and at each biweekly assessment visit over 12 weeks of treatment.</description>
        <time_frame>Biweekly from Baseline (week zero) to 12 weeks</time_frame>
        <population>Intent to treat sample. Subjects with at least one post baseline visit recorded with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Maca Root</title>
            <description>Subjects in this arm will be given 3g/day of Maca Root.&#xD;
Maca Root: 3g/day of Maca Root for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects in this arm will receive inactive placebo.&#xD;
Placebo: Placebo provided by research pharmacy daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Reductions in Massachusetts General Hospital Sexual Dysfunction (MGH-SD) Inventory Scores Over 12 Weeks of Treatment.</title>
          <description>This instrument is composed of five items evaluating libido, sexual arousal or excitement, ability to achieve orgasm, ability to achieve and maintain an erection (for men only) and overall sexual satisfaction. Items are rated on a scale of 1 to 6 with a rating of 1 indicating greater than normal functioning and a rating of 6 indicating totally absent functioning. Possible total scores range from 5-30, with higher scores indicating greater pathology. Scores were obtained at baseline and at each biweekly assessment visit over 12 weeks of treatment.</description>
          <population>Intent to treat sample. Subjects with at least one post baseline visit recorded with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MGH-SD Score-Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" spread="2"/>
                    <measurement group_id="O2" value="18.7" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MGH-SD Score-Final</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" spread="5.0"/>
                    <measurement group_id="O2" value="18" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in MGH-SD Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="6.1"/>
                    <measurement group_id="O2" value="-0.7" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There will be no difference in clinical improvement (i.e. change in MGH-SD score) between treatment arms. No formal power analysis was carried out, given the small study sample.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Analysis is a test of statistical significance to evaluate whether the results are consistent with the assumption of there being no difference in the clinical improvement (i.e. change in MGH-SD score) of the two treatments (null hypothesis).</non_inferiority_desc>
            <p_value>0.38</p_value>
            <p_value_desc>No adjustment for multiple comparisons. P value for significance set a priori at P&lt;0.05.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.6</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>4.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.7</ci_lower_limit>
            <ci_upper_limit>13.97</ci_upper_limit>
            <other_analysis_desc>Analysis was not truly informative since the analyzable sample (n=6) was too small. Results should be interpreted with caution.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years.</time_frame>
      <desc>All adverse events were systematically recorded and reported to the Institutional Review Board (IRB). All significant adverse effects were immediately reported upon their discovery and monitored through the following methods: 1) Going over any adverse events with the patient at each study visit 2) holding weekly meetings with the principal investigator and study staff team to review all safety and tolerability issues that were brought up.</desc>
      <group_list>
        <group group_id="E1">
          <title>Maca Root</title>
          <description>Subjects in this arm will be given 3g/day of Maca Root.&#xD;
Maca Root: 3g/day of Maca Root for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Subjects in this arm will receive inactive placebo.&#xD;
Placebo: Placebo provided by research pharmacy daily for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>SNOMED CT</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <description>Severe bleeding during menstrual period.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>SNOMED CT</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bloating</sub_title>
                <description>Sensation of bloating</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Heartburn symptom</sub_title>
                <description>General stomach upset</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Nausea sensation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Generalized fatigue</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Superficial laceration of leg</sub_title>
                <description>Accidental cut on leg</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Forgetfulness</sub_title>
                <description>Generalized forgetfulness of tasks, appointments.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <description>increased generalized anxiety</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal bleeding</sub_title>
                <description>Mild bleeding from vagina outside of regular menstrual periods.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <description>Flu</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <description>Common cold</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <description>Sore throat in absence of other upper respiratory symptoms.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was never completed due to low enrollment. Only 8 of a projected 80 subjects were randomized over a period of 2 years. Sample is too small to yield useful information.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. David Mischoulon, Director</name_or_title>
      <organization>Depression Clinical and Research Program, Massachusetts General Hospital</organization>
      <phone>617-724-5198</phone>
      <email>dmischoulon@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

